An improved imaging agent for malignant melanoma, based on [Nle4,D-Phe7]alpha-melanocyte stimulating hormone

Area of Science:

• Bioconjugate Chemistry
• Radiopharmaceutical Development
• Molecular Imaging

Background:

• Alpha-melanocyte stimulating hormone (α-MSH) analogs are explored for targeted cancer therapies.
• Diethylenetriamine pentaacetic acid (DTPA) is a chelator used for radiolabeling.

Purpose of the Study:

• To synthesize and evaluate novel α-MSH derivatives, monoNDP-MSH-DTPA and bisNDP-MSH-DTPA, for melanoma imaging.
• To assess their ability to stably chelate indium-111 (¹¹¹In) and target melanomas.

Main Methods:

• Synthesis of monoNDP-MSH-DTPA and bisNDP-MSH-DTPA by linking peptide sequences to DTPA.
• Radiolabeling with ¹¹¹In and evaluation of hormonal activity.
• In vivo studies in DBA2 mice bearing Cloudman S91 melanomas to assess tumor targeting, biodistribution, and imaging.

Main Results:

• Both compounds exhibited stable ¹¹¹In binding and comparable or superior hormonal activity to α-MSH.
• Both compounds successfully targeted ¹¹¹In to Cloudman S91 melanomas.
• MonoNDP-MSH-DTPA demonstrated higher tumor:blood and tumor:tissue ratios with less non-specific uptake in the liver and kidneys.
• Radioscintigraphy revealed good tumor localization within 2 hours post-injection for both compounds.

Conclusions:

• MonoNDP-MSH-DTPA exhibits favorable characteristics for melanoma imaging, including efficient tumor targeting, rapid clearance from circulation, and minimal non-specific uptake.
• MonoNDP-MSH-DTPA shows significant promise as a clinical melanoma imaging agent.